期刊
NEUROSURGERY
卷 54, 期 6, 页码 1480-1488出版社
OXFORD UNIV PRESS INC
DOI: 10.1227/01.NEU.0000125006.88478.F6
关键词
antagonist; epidermal growth factor receptor; gliomas; targeted chemotherapy
OVERACTIVATION OF EPIDERMAL growth factor receptor (EGFR) signaling has been recognized as an important step in the pathogenesis and progression of multiple forms of cancer of epithelial origin. This knowledge has led to a surge of interest in novel anticancer therapies targeting key constituents of the EGFR signal transduction pathway. Several molecular strategies have been developed recently to modulate either EGFR or the downstream signal beyond the cell surface receptor. The important role of aberrant EGFR signaling in the progression of malignant gliomas makes EGFR-targeted therapies of particular interest in this form of cancer. The use of anti-EGFR therapies against malignant brain tumors, although in its infancy, promises to yield although in its infancy therapy exciting results as these new drugs probably will enhance the usefulness of existing therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据